Capacity as ConstraintNarrow moat

In an unusual and telling reversal, Lilly's binding constraint on its biggest drugs has not been demand but its own ability to manufacture enough — the incretins have sold as fast as Lilly can make them, and for a stretch the company simply could not produce sufficient supply to meet the extraordinary demand. When capacity, not customers, is the ceiling, manufacturing scale becomes a direct competitive weapon: whoever can make the most of a wanted drug captures the most of the market.

This turns manufacturing investment into a growth lever and a moat at once. Lilly has committed tens of billions of dollars to building new plants and expanding capacity precisely because every additional dose it can produce is a dose it can sell, and because supply is a way to win share that rivals, equally capacity-constrained, cannot easily match. The company that builds capacity fastest in a supply-limited market captures demand its competitors must leave on the table — a rare situation where spending on factories directly buys revenue and share.

The double edge is that being capacity-constrained is also a failure to fully capitalize on the opportunity — every patient who cannot get the drug is revenue forgone and a chance for a rival or a compounded copy to fill the gap — and that the enormous capital committed to capacity is a bet that demand persists at levels justifying it. If demand eventually softens or competition catches up, that capacity could become excess. So capacity as constraint is, for now, a sign of enviable demand and a spur to advantageous investment, but it reflects a supply failure as much as a strength, and the huge build-out it justifies — ~$50 billion of announced plants¹ — carries the risk of any large bet on the future.